INDICATIONS

Netupitant/palonosetron, in a fixed-dose combination, is approved for the prevention of acute and delayed nausea and vomiting associated with initial and repeat doses of chemotherapy, including, but not limited to, highly emetogenic chemotherapy (HEC) regimens.^1,2 See Table 1 for a comparison of US Food and Drug Administration (FDA)–approved -indications for 5-HT₃ antagonists and neurokinin 1 (NK₁) inhibitors.^1,3-14 

CLINICAL PHARMACOLOGY

Chemotherapy-induced nausea and vomiting (CINV) is a commonly occurring adverse event following use of chemotherapeutic regimens for treatment of cancers.¹⁵ Multiple patient risk factors (eg, age, gender, alcohol consumption) have been identified along with the emetogenic potential of individual or combination chemotherapeutic agents.^15,16 The exact mechanism is unclear, but acute-phase nausea is potentially due to the release of serotonin (5-HT) by enterochromaffin cells in the gastrointestinal (GI) tract.^1,15 The delayed phase is thought to be due to substance P activation of NK₁ receptors.¹ Activation of NK₁ receptors, both centrally and peripherally, by substance P is involved in multiple physiologic pathways, including pain and migraine regulation, nausea and vomiting, mood and anxiety levels, alcoholism, and inflammatory conditions of the GI tract.^17,18 

In vitro models show that netupitant inhibits the action of substance P at the human NK₁ receptor in a concentration-dependent manner, and a human -positron emission tomography study showed that netupitant is able to cross the blood-brain barrier.^17,18 Netupitant is present in the frontal and occipital cortex, the striatum, the anterior cingulate, and the lateral and medial temporal cortex.¹⁸ Palonosetron is a 5-HT₃ receptor antagonist that inhibits the serotonin secreted from stimulation by chemotherapy.¹ An in vitro model showed that the combination of netupitant and palonosetron inhibited activation of NK₁ receptors by substance P in a synergistic manner; neither chemical alone inhibited activation at the synergistic concentrations studied.¹⁹ Netupitant and palonosetron had no action at NK₂ or NK₃ receptors.¹⁹ 

PHARMACOKINETICS

Combinations of netupitant 200 to 600 mg and palonosetron 0.5 to 1.5 mg have total exposure (area under the curve [AUC]) and mean maximum concentration (C_max) best characterized by a linear pharmacokinetic model.²⁰ Between-subject variability is between 42% and 56% for netupitant 200 to 600 mg and between 20% and 29% for palonosetron 0.5 to 1.5 mg.²⁰ At the doses studied, netupitant and palonosetron have no effect on the pharmacokinetic parameters of each other.^1,21 

Following oral administration of netupitant and palonosetron in healthy subjects, the time to maximum concentration (T_max) is about 5 hours for both drugs.¹ Additionally, coadministration with food, presence of cancer, or subsequent administration of chemotherapy have no effect on the pharmacokinetic parameters of netupitant and palonosetron.¹ 

Netupitant monotherapy has linear pharmacokinetics in regard to C_max and AUC in single doses ranging from 100 to 450 mg.¹⁸ After oral administration of netupitant, T_max is about 5 hours.^1,18 Netupitant and its metabolites (M1, M2, and M3) are highly bound in plasma proteins (99.5% netupitant, 97.5% metabolites).¹ Netupitant undergoes significant metabolism to a multitude of metabolites via both phase 1 and phase 2 processes. The primary metabolites M1, M2, and M3 account for 29%, 14%, and 33%, respectively, of the circulating exposure to netupitant; these metabolites are active in animal models.^1,18 The approximate half-life after a single dose of netupitant in cancer patients is 80 hours.¹ Netupitant 300 mg has a long duration of receptor occupancy at 96 hours, which contributes to its duration of effect.¹⁸ 

Following oral administration of radiolabeled netupitant, half of the radioactivity is recovered in feces and urine 120 hours post dose; 70% and 4% of the drug are recovered in feces and urine, respectively, by 336 hours; and 86.5% and 4.8% of the drug are recovered in feces and urine, respectively, by 30 days post dose. Radioactivity is recovered primarily as metabolites.¹⁸ 

Palonosetron monotherapy (3 to 80 mcg/kg in healthy subjects) demonstrates dose-proportional pharmacokinetics. After oral administration, bioavailability is 97%. Palonosetron is approximately 62% bound to plasma proteins. Primary metabolism is via cytochrome P450 (CYP-450) 2D6 and, to a lesser extent, 3A4 and 1A2. The half-life of palonosetron in patients with cancer is 48 hours.¹ 

The pharmacokinetic parameters for the 5-HT₃ antagonists and NK₁ inhibitors are compared in Table 2.^1,3-14

COMPARATIVE EFFICACY

Indication: Prevention of Chemotherapy-Induced Nausea and Vomiting 

Guidelines 

Guideline:European Society of Medical Oncology/Multinational Association of Supportive Care in Cancer (ESMO/MASCC) Guidelines Working Group; guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting 

Reference: Roila F, et al, 2010¹⁶ 

Comments: In patients undergoing HEC, prevention of acute nausea and vomiting should include a 5-HT₃ antagonist, dexamethasone, and aprepitant. All patients receiving cisplatin should receive antiemetic therapy to prevent delayed nausea and vomiting; a recommended treatment for both acute and delayed nausea and vomiting is a 5-HT₃ antagonist plus dexamethasone plus aprepitant on day 1, followed by aprepitant plus dexamethasone on days 2 to 3 and dexamethasone alone on day 4. The guidelines recommend NK₁ antagonists as a class; at the time these guidelines were published, aprepitant was the only approved NK₁ antagonist. In patients undergoing treatment with moderately emetogenic chemotherapy (MEC) containing anthracycline/cyclophosphamide, a 5-HT₃ antagonist plus dexamethasone plus aprepitant is recommended on day 1 followed by aprepitant on days 2 to 3. For MEC not containing anthracycline/cyclophosphamide, palonosetron plus dexamethasone on day 1 followed by dexamethasone on days 2 to 3 is recommended. No difference has been reported between oral and parenteral dosage forms. These guidelines were published prior to approval of the netupitant/palonosetron combination. 

Studies

Drug: Netupitant/Palonosetron plus Dexamethasone vs Palonosetron plus Dexamethasone 

Reference: Aapro M, et al, 2014²² 

Study Design: Randomized, double-blind, double-dummy, active-controlled, multicenter study 

Study Funding: Helsinn Healthcare, SA 

Patients: 1,450 patients 18 years and older with an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 who were naive to chemotherapy for a solid tumor and scheduled to receive their first course of an anthracycline/cyclophosphamide-containing MEC regimen. Key exclusion criteria included planned HEC on days 1 to 5 or additional MEC on days 2 to 5, radiation therapy, or bone marrow or stem-cell transplant. Patients could not use medications with known emetogenic efficacy within 24 hours prior to day 1 and were excluded if they experienced vomiting, retching, or mild nausea within 24 hours prior to day 1. Additional exclusion criteria included a history of cardiovascular disease, conduction abnormalities (except incomplete right bundle branch block), use of CYP3A4 inducers within 4 weeks, use of strong or moderate CYP3A4 inhibitors within 1 week, and concomitant use of inducers or substrates. Median age was 54 years, 98% were women, and approximately 80% were White; approximately 97.5% had breast cancer, approximately 99% had an ECOG performance status of 0 or 1, and 63.7% to 68% received doxorubicin. 

Intervention: Patients were randomized 1:1 to receive netupitant 300 mg/palonosetron 0.5 mg plus dexamethasone 12 mg or palonosetron 0.5 mg plus dexamethasone 20 mg on day 1 prior to -chemotherapy. Netupitant/palonosetron or palonosetron was administered 60 minutes prior to chemotherapy, and dexamethasone was administered 30 minutes prior to chemotherapy. Chemotherapeutic regimens contained cyclophosphamide 500 to 1,500 mg/m² and either doxorubicin (at least 40 mg/m²) or epirubicin (at least 60 mg/m²). Investigators were provided metoclopramide tablets as rescue treatment, but could use alternative rescue treatment at their own discretion (excluding 5-HT₃ antagonists, NK₁ antagonists). Use of rescue medication was considered treatment failure. 

Results 

Primary Endpoint(s) 

• Proportion of patients with a complete response (no emesis, no rescue medication) during the delayed phase (25 to 120 hours) was 76.9% with netupitant/palonosetron and 69.5% with palonosetron (P = .001). Number needed to treat (NNT) with netupitant/palonosetron compared with palonosetron alone was 13.5. 

Secondary Endpoint(s) 

• Proportion of patients with a complete response during the acute phase (0 to 24 hours) was 88.4% with netupitant/palonosetron and 85% with palonosetron (P = .047; NNT = 29.4). 
• Proportion of patients with a complete response overall (0 to 120 hours) was 74.3% with netupitant/palonosetron and 66.6% with palonosetron (P = .001; NNT = 13). 
• Proportion of patients with complete protection (complete response without significant nausea) with netupitant/palonosetron and palonosetron during the acute phase (82.3% vs
  81.1%; P = .528), delayed phase (67.3% vs 60.3%; P = .005; NNT = 14.3), and overall period (63.8% vs 57.9%; P = .02; NNT = 17). 
• Proportion of patients with no significant nausea (visual analog score less than 25 mm) with netupitant/palonosetron and palonosetron during the acute phase (87.3% vs 87.9%;
  P = 0.747), delayed phase (76.9% vs 71.3%; P = .014; NNT = 17.9), and overall period (74.6% vs 69.1%; P = .02; NNT = 18.2). 
• Proportion of patients with no emesis with netupitant/palonosetron and palonosetron during the acute phase (90.9% vs 87.3%; P = .025; NNT = 27.8), delayed phase (81.8% vs 75.6%; P = .004; NNT = 16.1), and overall period (79.8% vs 72.1%; P < .001; NNT = 13). 

Endpoint(s) 

• Proportion of patients for whom nausea and vomiting had no impact on daily life based on Functional Living Index-Emesis (FLIE) questionnaire score was 78.5% with netupitant/palonosetron and 72.1% with palonosetron (P = .005; NNT = 15.6). 
• The most commonly reported adverse events were headache and constipation and were reported at similar rates between groups. 

Comments: This was a phase 3 pivotal trial. The trial showed an improvement in nausea and vomiting over palonosetron in women undergoing their first treatment for breast cancer with a combination of cyclophosphamide and either doxorubicin or epirubicin. This study does not show an effect on anticipatory nausea. Stratification was based on region and age (younger than 55 years [51.2%] or 55 years and older [48.8%]). Patients were eligible to enter an extension trial for repeat consecutive cycles of chemotherapy. A safety trial reported by Gralla and colleagues randomized 413 patients (1,961 chemotherapy cycles; 76% MEC and 24% HEC) 3:1 to receive either palonosetron plus netupitant or palonosetron plus aprepitant.²³ A total of 75% of patients completed at least 4 cycles. Over multiple cycles, 10.1% of patients experienced treatment-related adverse events in the netupitant arm, and 5.8% experienced treatment-related adverse events in the aprepitant arm (number needed to harm [NNH] of 23); the most commonly reported adverse event of multiple cycles was constipation (3.6% with netupitant; 1% with aprepitant). Efficacy (complete response rates) was sustained over 6 cycles of chemotherapy and was similar between the 2 treatment arms. The safety study excluded patients with breast cancer -receiving anthracycline/cyclophosphamide-containing MEC. 

Limitations: The study did not include a significant proportion of male subjects because the majority of patients had been diagnosed with breast cancer. 

Drug: Netupitant/Palonosetron plus Dexamethasone vs Palonosetron plus Dexamethasone vs Aprepitant plus Ondansetron plus Dexamethasone 

Reference: Hesketh PJ, et al, 2014²⁴ 

Study Design: Randomized, double-blind, double-dummy, active-controlled, multicenter study 

Study Funding: Helsinn Healthcare, SA 

Patients: 694 patients 18 years and older with a Karnofsky performance score of at least 70% and who were naive to chemotherapy and scheduled to receive their first course of cisplatin (50 mg/m² or greater) alone or in combination for the treatment of a malignant tumor. Key exclusion criteria included planned HEC or MEC on days 2 to 5, moderately or highly emetogenic radiotherapy, or bone marrow or stem-cell transplant. Patients were not allowed to use medications with known emetogenic efficacy within 24 hours prior to day 1 or systemic corticosteroids within 72 hours of day 1. Patients were also excluded if they experienced vomiting, retching, or mild nausea within 24 hours prior to day 1. Additional exclusion criteria included a history of or predisposition to cardiovascular disease and conduction abnormalities (except incomplete right bundle branch block). Use of CYP3A4 inducers within 4 weeks, use of strong or moderate CYP3A4 inhibitors within 1 week, and concomitant use of inducers or substrates were prohibited. Median age was 55 years and approximately 57% were men; approximately 57% did not use alcohol, approximately 50% had lung, head, and neck cancers; approximately 60% had a Karnofsky performance score of 90%; approximately 50% received cisplatin plus a low emetogenic therapy; and approximately 35% received cisplatin plus MEC or HEC. 

Intervention: Patients were evenly randomized to 1 of 5 of the following treatment arms: placebo plus palonosetron 0.5 mg plus oral dexamethasone 20 mg on day 1, followed by oral dexamethasone 8 mg twice daily on days 2 to 4 (palonosetron 0.5 mg alone); oral netupitant 100, 200, or 300 mg plus palonosetron 0.5 mg plus dexamethasone 12 mg on day 1, followed by dexamethasone 4 mg twice daily on days 2 to 4; or oral aprepitant 125 mg plus IV ondansetron 32 mg plus oral dexamethasone 12 mg on day 1 followed by oral aprepitant 80 mg daily and dexamethasone 4 mg twice daily for days 2 to 3, and then followed by oral dexamethasone 4 mg twice daily on day 4 (aprepitant plus ondansetron). Investigators could use rescue treatment with the exclusion of 5-HT₃ antagonists or NK₁ antagonists. Use of rescue medication was considered treatment failure. 

Results 

Primary Endpoint(s) 

• Proportion of patients with a complete response during the overall period (0 to 120 hours) was 87.4% (P ≤ .05) with netupitant 100 mg plus palonosetron, 87.6% (P ≤ .05) with netupitant 200 mg plus palonosetron, 89.6% (P ≤ .01) with netupitant 300 mg plus palonosetron, 86.6% (P ≤ .05) with aprepitant plus ondansetron, and 76.5% with palonosetron 0.5 mg alone. NNT with netupitant 300 mg plus palonosetron versus palonosetron 0.5 mg alone was 7.6. 

Secondary Endpoint(s) 

• Proportion of patients with a complete response during the delayed phase (25 to 120 hours) was 90.4% (P ≤ .05) with netupitant 100 mg plus palonosetron, 91.2% (P ≤ .05) with netupitant 200 mg plus palonosetron, 90.4% (P ≤ .05) with netupitant 300 mg plus palonosetron, 88.8% (P ≤ .05) with aprepitant plus ondansetron, and 80.1% with palonosetron 0.5 mg alone. NNT for netupitant 300 mg plus palonosetron versus palonosetron 0.5 mg alone was 9.7. 
• Proportion of patients with a complete response during the acute phase (0 to 24 hours) was 93.3% with netupitant 100 mg plus palonosetron, 92.7% with netupitant 200 mg plus palonosetron, 98.5% (P ≤ .05) with netupitant 300 mg plus palonosetron, 94.8% with aprepitant plus ondansetron, and 89.7% with palonosetron 0.5 mg alone. NNT with netupitant 300 mg plus palonosetron versus palonosetron 0.5 mg alone was 11.4. 
• Additional results are presented in Table 3.

Endpoint(s) 

• The most common adverse events in all palonosetron arms were hiccups, headache, and leukocytosis. 

Comments: This was a phase 2 pivotal, dose-ranging trial. Stratification was based on gender, and subgroup analysis suggested that netupitant plus palonosetron elicited more of a benefit in women than in men. The study was not powered to show a difference between aprepitant and netupitant arms, and all analyses of aprepitant compared with the palonosetron-only arm were post hoc. 

Limitations: The trial was not conducted at US sites. 

CONTRAINDICATIONS, WARNINGS, AND PRECAUTIONS 

The contraindications, warnings, precautions, and use in special populations for the 5-HT₃ antagonists and NK₁ inhibitors are summarized in Tables 4 and 5.^1,3-14

Contraindications 

No contraindications are listed in the prescribing information.¹ Hypersensitivity to active -ingredient or any inactive ingredients (eg, microcrystalline cellulose, sucrose fatty acid esters, povidone K-30, croscarmellose sodium, silicon dioxide, sodium stearyl fumarate, magnesium stearate, monoglycerides and diglycerides of capryl/capric acid, glycerin, polyglyceryl oleate, butylated hydroxyanisole, gelatin, -sorbitol, titanium dioxide, yellow iron oxide, and red iron oxide; trace amounts of medium-chain triglycerides, lecithin, and denatured ethanol) should be considered a contraindication to therapy.¹ 

Warnings and Precautions 

Hypersensitivity reactions have been reported in patients treated with 5-HT₃ receptor antagonists. These reactions were reported in patients with and without known hypersensitivity to other 5-HT₃ receptor antagonists.¹ 

Serotonin syndrome, sometimes fatal, has been reported with use of 5-HT₃ receptor antagonists. Most cases have been observed when 5-HT₃ receptor antagonists are used in conjunction with other serotonergic drugs (eg, selective serotonin reuptake inhibitors [SSRIs], serotonin-norepinephrine reuptake inhibitors [SNRIs], monoamine oxidase inhibitors [MAOIs], mirtazapine, fentanyl, lithium, tramadol, IV methylene blue) or in cases of overdose with other 5-HT₃ receptor antagonists. Most cases of serotonin syndrome have occurred in patients in postanesthesia care units or infusion centers.¹ Patients should be educated to recognize and report signs and symptoms of serotonin syndrome, including mental status changes (eg, agitation, hallucinations, delirium, coma), autonomic instability (eg, tachycardia, labile blood pressure, dizziness, diaphoresis, flushing, hyperthermia), neuromuscular symptoms (eg, tremor, rigidity, myoclonus, hyperreflexia, incoordination), seizures, and potential GI symptoms (eg, nausea, vomiting, diarrhea). If serotonin syndrome occurs, immediately discontinue netupitant/palonosetron.¹ 

A placebo-controlled QTc study showed that doses ranging from netupitant 200 mg/palonosetron 0.5 mg to netupitant 600 mg/palonosetron 1.5 mg did not clinically increase the QTc interval compared with placebo.^1,20 

Netupitant is classified as Pregnancy Category C; no adequate and well-controlled studies have been performed in pregnant women. Netupitant/palonosetron should only be used in pregnancy if the benefits clearly outweigh the risks. Administration of doses up to 3.7 times the human exposure to pregnant rats did not lead to fetal abnormalities. Administration of doses at least 0.2 times the human exposure did lead to fetal abnormalities in pregnant rabbits.¹ 

It is not known if netupitant/palonosetron is excreted in human breast milk. Because many drugs are excreted in human breast milk, caution should be used and a decision to discontinue netupitant/palonosetron or breast-feeding should be made.¹ 

Safety and efficacy have not been established in patients younger than 18 years.¹ 

No dosage adjustment is required for patients with mild to moderate hepatic impairment (Child-Pugh score of 5 to 8). Limited data are available concerning the use of netupitant/palonosetron in patients with severe hepatic impairment (Child-Pugh score of 9 or greater); netupitant/palonosetron should be avoided in these patients.¹ 

No dosage adjustment is required for patients with mild to moderate renal impairment. Although severe renal impairment did not significantly affect the pharmacokinetics of netupitant/palonosetron, safety and efficacy have not been established in this population. Netupitant/palonosetron should be avoided in patients with severe renal impairment or end-stage renal disease requiring hemodialysis.¹ 

ADVERSE REACTIONS

The most commonly reported adverse reactions in patients receiving netupitant/palonosetron compared with those receiving palonosetron prior to HEC were dyspepsia (4% vs 2%), fatigue (4% vs 2%), constipation (3% vs 1%), and erythema (3% vs 2%). For patients receiving netupitant/palonosetron or palonosetron prior to MEC (eg, anthracyclines, cyclophosphamide-based chemotherapy), the most common adverse events were headache (9% vs 7%), asthenia (8% vs 7%), and fatigue (7% vs 5%).¹ 

Abnormal laboratory values in patients treated with netupitant/palonosetron or palonosetron were aspartate aminotransferase (AST) greater than 3 times the upper limit of normal (ULN) and/or alanine aminotransferase (ALT) greater than 3 times the ULN with total bilirubin greater than ULN (0.3% vs 0.6%); AST greater than 10 times the ULN and/or ALT greater than 10 times the ULN with total bilirubin greater than the ULN (0% vs 0.2%); and AST greater than 3 times the ULN and/or ALT greater than 3 times the ULN with total bilirubin 2 times the ULN or greater (0.1% vs 0.1%).¹ 

In a trial for the treatment of overactive bladder, healthy patients undergoing daily dosing of netupitant 200 mg for up to 8 weeks had a higher rate of somnolence (10% vs 5%), headache (3.3% vs 0%), first-degree atrioventricular block (3.3% vs 1.7%), tachycardia (3.3% vs 0%), and nausea (3.3% vs 0%) compared with the placebo group.²⁵ 

DRUG INTERACTIONS 

Coadministration of netupitant and midazolam (a CYP3A4 substrate) increased midazolam’s C_max by 40%, AUC_inf by 144%, and mean half-life by 64%. The clearance of midazolam was decreased 52%. The pharmacokinetics of netupitant were not affected by the presence of midazolam.^1,26 Caution should be used when administering netupitant/palonosetron with benzodiazepines metabolized via CYP3A4 (eg, alprazolam, midazolam, triazolam).¹ 

Coadministration of netupitant and erythromycin increased erythromycin’s C_max by 30%, AUC_inf by 30%, and mean half-life by 17%. The clearance of erythromycin was decreased by 44%. The pharmacokinetics of netupitant were not affected by the presence of erythromycin.²⁶ 

Coadministration of netupitant 300 mg and dexamethasone (20 mg on day 1 followed by 8 mg twice daily on days 2 to 4) increased dexamethasone’s AUC_0-24 by 72% on day 1, AUC_24-36 by 143% on day 2, AUC_84-108 by 140%, and AUC_84-inf by 140% compared with dexamethasone alone. The C_max of dexamethasone was increased by 11% on day 1, by 66% on day 2, and by 75% on day 4. The half-life of dexamethasone was increased by 1.9 to 3.2 hours on day 1 and by 2 to 2.4 hours on day 4. The pharmacokinetics of netupitant were not affected by the presence of dexamethasone.^1,26 A dosage reduction is recommended for dexamethasone.¹ 

Coadministration of netupitant/palonosetron with chemotherapeutic agents metabolized by CYP3A4 (eg, docetaxel, paclitaxel, etoposide, irinotecan, cyclophosphamide, ifosfamide, imatinib, vinorelbine, vinblastine, vincristine) may increase the systemic exposure of these chemotherapeutic agents. Caution should be used, and patients should be monitored closely for adverse reactions due to chemotherapy.¹ One study reported that coadministration of netupitant/palonosetron and cyclophosphamide did not lead to increased rates of adverse events (neutropenia, alopecia, and leukopenia) over at least 4 cycles of chemotherapy.²⁷ 

Coadministration of oral contraceptives containing levonorgestrel and ethinyl estradiol with netupitant/palonosetron is unlikely to affect the efficacy of the oral contraceptive.^1,21 

Coadministration of strong inducers of CYP3A4 (eg, rifampin) may reduce the efficacy of netupitant/palonosetron by reducing the plasma concentrations of netupitant. Avoid coadministration of strong inducers of CYP3A4 and netupitant/palonosetron.^1,21 

Coadministration of strong inhibitors of CYP3A4 (eg, ketoconazole) may increase the systemic exposure of netupitant. No dosage adjustment is recommended.^1,21 

Coadministration of serotonergic drugs and netupitant/palonosetron may put patients at risk of serotonin syndrome. Monitor for and educate patients about the signs and symptoms of serotonin syndrome during treatment with netupitant/palonosetron.¹ 

Coadministration of digoxin and netupitant 450 mg did not significantly affect the pharmacokinetics of digoxin. Administration of netupitant and P-glycoprotein may not require dosage adjustments.²⁸ 

RECOMMENDED MONITORING 

All patients should be monitored for adverse events due to excessive levels of chemotherapeutic agents metabolized by CYP3A4. Additionally, when multiple serotonergic agents are used, patients should be monitored for signs and symptoms of serotonin syndrome.¹ 

Patients should be both warned of increased sedation due to benzodiazepines metabolized by CYP3A4 and monitored for these effects. The increased effect of benzodiazepines can last for multiple days.¹ 

DOSING

The recommended dose for patients undergoing HEC is 1 capsule of netupitant 300 mg/palonosetron 0.5 mg orally 1 hour prior to chemotherapy, followed by dexamethasone 12 mg 30 minutes prior to chemotherapy on day 1. Additionally, patients should be administered dexamethasone 8 mg orally once daily on days 2 through 4.¹ 

For patients undergoing MEC (eg, anthracyclines, cyclophosphamide-based chemotherapy, chemotherapy not considered to be highly emetogenic), the recommended dose is 1 capsule of netupitant 300 mg/palonosetron 0.5 mg orally 1 hour prior to chemotherapy, followed by dexamethasone 12 mg orally 30 minutes prior to chemotherapy on day 1. Administration of dexamethasone on days 2 to 4 is not necessary.¹

Netupitant/palonosetron can be taken without regard to food.¹ 

Dosing for 5-HT₃ antagonists and NK₁ inhibitors for CINV and postoperative nausea and vomiting (PONV) are summarized in Table 6 and Table 7, respectively.^{1,3,5,6,12-14}

PRODUCT AVAILABILITY 

Netupitant/palonosetron was approved by the FDA on October 10, 2014.² It is available as a pack of 1 hard gelatin, white and caramel-colored capsule containing 3 netupitant 100 mg tablets and 1 palonosetron 0.5 mg gelatin capsule.¹ 

Netupitant/palonosetron should be stored between 68°F and 77°F (20°C and 25°C), with excursions permitted between 59°F and 86°F (15°C and 30°C).¹ 

The availability of 5-HT₃ antagonists and NK₁ inhibitors is summarized in Table 8.^1,3-14,29

DRUG SAFETY/RISK EVALUATION AND MITIGATION STRATEGY (REMS)

No REMS is required for netupitant/palonosetron.² 

CONCLUSION

Netupitant/palonosetron is the first approved combination product containing a 5-HT₃ -receptor antagonist and an NK₁ receptor antagonist. ESMO/MASCC guidelines recommend combination -therapy for HEC regimens. The efficacy studies used a single dose with an extension or a 6-cycle dose. One study included aprepitant with ondansetron, but the study was not designed to compare netupitant/palonosetron with this arm and did not perform statistical analysis between the groups. While palonosetron was previously approved and has been used clinically in a large population, experience with netupitant is limited. Netupitant monotherapy was studied for a different indication at a dose of 200 mg daily for 8 weeks and showed an adverse effect profile similar to those of short-term studies. Netupitant/palonosetron has not been studied for the -treatment of nausea. 

REFERENCES 

1. Akynzeo (netupitant and palonosetron capsules) [prescribing information]. Woodcliff Lake, NJ: Eisai Inc; October 2014. 
2. Beitz JG. NDA approval letter: Akynzeo (netupitant and palonosetron NDA 205718). US Food and Drug Administration Web site. http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2014/205718Orig1s000ltr.pdf. Published October 10, 2014. Accessed October 14, 2014. 
3. Aloxi (palonosetron) [prescribing information]. Woodcliff Lake, NJ: Eisai Inc; September 2014. 
4. Anzemet (dolasetron tablets) [prescribing information]. Bridgewater, NJ: Sanofi-Aventis US; September 2014. 
5. Anzemet (dolasetron injection) [prescribing information]. Bridgewater, NJ: Sanofi-Aventis US; September 2014. 
6. Emend (aprepitant capsules) [prescribing information]. Whitehouse Station, NJ: Merck & Co; August 2014. 
7. Emend (fosaprepitant injection) [prescribing information]. Whitehouse Station, NJ: Merck & Co; August 2014. 
8. Granisetron injection [prescribing information]. Lake Zurich, IL: Fresenius Kabi; August 2014. 
9. Granisetron tablets [prescribing information]. Sellersville, PA: Teva Pharmaceuticals; August 2014. 
10. Granisol (granisetron oral solution) [prescribing information]. Califon, NJ: PediatRx; November 2010. 
11. Sancuso (granisetron transdermal) [prescribing information]. Bridgewater, NJ: ProStrakan Inc; September 2014. 
12. Zofran (ondansetron injection) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; September 2014. 
13. Zofran (ondansetron oral tablets, orally disintegrating tablets, oral solution) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; September 2014. 
14. Zuplenz (ondansetron oral film) [prescribing information]. Portland, OR: Galena Biopharma; September 2014. 
15. Hesketh PJ. Chemotherapy-induced nausea and vomiting. N Engl J Med. 2008;358(23):2482-2494. 
16. Roila F, Herrstedt J, Aapro M, et al; ESMO/MASCC Guidelines Working Group. Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: Results of the Perugia consensus conference. Ann Oncol. 2010;21(suppl 5):v232-v243. 
17. Rizzi A, Campi B, Camarda V, et al. In vitro and in vivo pharmacological characterization of the novel NK₁ receptor selective antagonist netupitant. Peptides. 2012;37(1):86-97. 
18. Spinelli T, Calcagnile S, Giuliano C, et al. Netupitant PET imaging and ADME studies in humans. J Clin Pharmacol. 2014;54(1):97-108. 
19. Stathis M, Pietra C, Rojas C, Slusher BS. Inhibition of substance P-mediated responses in NG108-15 cells by netupitant and palonosetron exhibit synergistic effects. Eur J Pharmacol. 2012;689(1-3):25-30. 
20. Spinelli T, Moresino C, Baumann S, Timmer W, Schultz A. Effects of combined netupitant and palonosetron (NEPA), a cancer supportive care antiemetic, on the ECG of healthy subjects: An ICH E14 thorough QT trial. Springerplus. 2014;3:389. 
21. Calcagnile S, Lanzarotti C, Rossi G, Henriksson A, Kammerer KP, Timmer W. Effect of netupitant, a highly selective NK₁ receptor antagonist, on the pharmacokinetics of palonosetron and impact of the fixed dose combination of netupitant and palonosetron when coadministered with ketoconazole, rifampicin, and oral contraceptives. Support Care Cancer. 2013;21(10):2879-2987. 
22. Aapro M, Rugo H, Rossi G, et al. A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy. Ann Oncol. 2014;25(7):1328-1333. 
23. Gralla RJ, Bosnjak SM, Hontsa A, et al. A phase III study evaluating the safety and efficacy of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting over repeated cycles of chemotherapy. Ann Oncol. 2014;25(7):1333-1339. 
24. Hesketh PJ, Rossi G, Rizzi G, et al. Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: A randomized dose-ranging pivotal study. Ann Oncol. 2014;25(7):1340-1346. 
25. Haab F, Braticevici B, Krivoborodov G, Palmas M, Zufferli Russo M, Pietra C. Efficacy and safety of repeated dosing of netupitant, a neurokinin-1 receptor antagonist, in treating overactive bladder. Neurourol Urodyn. 2014;33(3):335-340. 
26. Lanzarotti C, Rossi G. Effect of netupitant, a highly selective NK₁ receptor antagonist, on the pharmacokinetics of midazolam, erythromycin, and dexamethasone. Support Care Cancer. 2013;21(10):2783-2791. 
27. Schwartzberg L, Oprean C, Cardona-Huerta S, et al. No evidence of increase cyclophosphamide toxicity associated with the antiemetic agent NEPA, a fixed-dose combination of netupitant and palonosetron [abstract]. Blood. 2013;122(21):2949. 
28. Baumann S, Tilola SO, Spinelli T, Timmer W. An evaluation of the drug interaction potential of netupitant with digoxin [abstract]. J Clin Oncol. 2012;30(suppl):abstract e19530. 
29. US National Library of Medicine. Ondansetron hydrochloride injection, solution. BD Rx Inc. NDC 76045-103-20. -DailyMed Web site. http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d89017aa-b8c3-4fd2-8e68-44e2cfd6f290. Updated April 2013. Accessed November 4, 2014. 

^*Founder and Contributing Editor, The Formulary;^†Drug Information Intern, College of Pharmacy, Washington State University Spokane; ^‡Director, Drug Information Center, and Professor of Pharmacy Practice, College of Pharmacy, Washington State University Spokane, PO Box 1495, Spokane, Washington 99210-1495. The authors indicate no relationships that could be perceived as a conflict of interest.